Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Kiniksa Pharmaceuticals, Ltd. (KNSA)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kiniksa Pharmaceuticals, Ltd. since year 2005.
Table 2 shows the detailed insider transactions of Kiniksa Pharmaceuticals, Ltd. since 2005.
The reporting company's ticker symbol is KNSA. The reporting company's CIK number is 1730430.
The total value of stock buying since 2005 is $71,686,922.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $18,600.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-10-07||Paolini John F. (SVP & Chief Medical Officer)||Option Ex||10,000||1.86||18,600|
|2018-05-29||Cormorant Global Healthcare Master Fund, Lp||Buy||69,444||18.00||1,249,992|
|2018-05-29||Deerfield Partners, L.p.||Buy||843,352||19.49||16,436,930|
|2018-05-29||Baker Julian (Director)||Buy||3,000,000||18.00||54,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises of KNSA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kiniksa Pharmaceuticals, Ltd. (symbol KNSA, CIK number 1730430) see the Securities and Exchange Commission (SEC) website.